A generic¹ targeted drug to treat cancer manufactured by a Chinese pharmaceutical² company hit market recently.

我国制药公司生产的一种仿制靶向抗癌药物于日前上市。

The new gefitinib cancer-treating drug, whose Chinese commercial name is Yiruike, was produced by Qilu Pharmaceutical (Qilu).

这款新上市的吉非替尼抗癌药由齐鲁制药研制，中文名是伊瑞可。

Its release ends an almost decade-long monopoly by Iressa, developed by British multinational³ biopharmaceutical company AstraZeneca and introduced to China in 2005.

伊瑞可的上市结束了易瑞沙在国内市场近10年的垄断。易瑞沙由英国跨国生物制药公司阿斯利康研制，于2005年引入国内。

Yiruike was approved for marketing⁴ by the China Food and Drug Administration after Iressa's patent protection expired in April 2016, Qilu said.

齐鲁制药称，易瑞沙的专利保护于2016年4月到期后，国家食品药品监督管理总局批准伊瑞可上市。

Qilu's general manager Li Yan said Yiruike, at less than RMB2,000 a pack, is a fraction of the price of the previously⁵ available drug, meaning more people in need can be helped.

齐鲁制药总经理李燕称，伊瑞可的售价不到2000元/盒，是此前能买到的药物的价格的一小部分，这意味着更多有需要的人可以得到帮助。

Gefitinib is a much-needed first line medicine used in targeted therapies against non-small-cell lung cancer, which accounts for about 80% of lung cancer cases in China.

吉非替尼是靶向治疗非小细胞肺癌的急需一线药物，非小细胞肺癌约占我国肺癌病例总数的80%。

Lung cancer kills more people than any other cancer in China. About 591,000 people die from lung cancer in China every year, according to the national cancer center. There are about 733,000 new cases every year.

在中国，肺癌的致死人数要多于其他任何癌症。根据国家癌症中心的数据显示，每年我国大约会有59.1万人因肺癌去世，此外每年还会有73.3万的新增病例。